Major clinical research advances in gynecologic cancer in 2017.
Dong Hoon SuhMiseon KimKyung-Hun LeeKeun Yong EomMaj Kamille KjeldsenMansoor Raza MirzaJae-Weon KimPublished in: Journal of gynecologic oncology (2019)
In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and update on sentinel lymph node mapping were reviewed for uterine corpus cancer. For ovarian cancer, 5 topics were selected including poly(ADP-ribose) polymerases inhibitors and immunotherapy. The other potential practice changers covered in this review were lymphadenectomy in advanced disease, secondary cytoreductive surgery in recurrent disease, weekly dose-dense regimen for first-line chemotherapy, incorporation of bevacizumab maintenance in platinum-sensitive recurrent disease, and effect of platinum-free interval prolongation. Conflicting opinions of academic societies on periodic pelvic examination were introduced in conjunction with relevant literature review. For the field of radiation oncology, results of 2 big trials, The Postoperative Radiation Therapy in Endometrial Carcinoma-3 and Gynecologic Oncology Group-258, for endometrial cancer and recent advance in high-dose-rate brachytherapy for cervical cancer were reported. Topics for breast cancer covered adjuvant capecitabine after preoperative chemotherapy, adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive disease, olaparib for metastatic cancer in patients with a germline BRCA mutation, 20-year risks of recurrence after stopping endocrine therapy at 5 years, and contemporary hormonal contraception and the risk of breast cancer.
Keyphrases
- endometrial cancer
- epidermal growth factor receptor
- radiation therapy
- papillary thyroid
- sentinel lymph node
- high dose
- early stage
- locally advanced
- monoclonal antibody
- squamous cell
- advanced non small cell lung cancer
- public health
- primary care
- neoadjuvant chemotherapy
- lymph node
- patients undergoing
- endothelial cells
- childhood cancer
- case report
- palliative care
- squamous cell carcinoma
- healthcare
- lymph node metastasis
- clinical trial
- high resolution
- dna repair
- stem cell transplantation
- phase ii study
- type diabetes
- coronary artery disease
- metastatic breast cancer
- metabolic syndrome
- skeletal muscle
- young adults
- coronary artery bypass
- insulin resistance
- big data
- high density
- atrial fibrillation
- dna damage
- double blind